Comparing Glaukos (NYSE:GKOS) & Iradimed (NASDAQ:IRMD)

Iradimed (NASDAQ:IRMD) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Insider & Institutional Ownership

92.3% of Iradimed shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 37.1% of Iradimed shares are held by company insiders. Comparatively, 6.4% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Iradimed and Glaukos”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iradimed	$65.56 million	9.74	$17.19 million	$1.46	34.51
Glaukos	$314.71 million	22.80	-$134.66 million	($3.26)	-40.06

Iradimed has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Iradimed and Glaukos, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iradimed	0	0	3	0	3.00
Glaukos	0	3	8	0	2.73

Iradimed currently has a consensus target price of $60.00, suggesting a potential upside of 19.07%. Glaukos has a consensus target price of $130.45, suggesting a potential downside of 0.10%. Given Iradimed’s stronger consensus rating and higher probable upside, analysts plainly believe Iradimed is more favorable than Glaukos.

Profitability

This table compares Iradimed and Glaukos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Iradimed	26.83%	24.71%	20.86%
Glaukos	-47.39%	-22.51%	-12.36%

Risk & Volatility

Iradimed has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Summary

Iradimed beats Glaukos on 9 of the 14 factors compared between the two stocks.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.